At this AEI event, experts discussed whether CER is likely to reduce costs without sacrificing the quality of care.

This paper analyses the impact of comparative effectiveness research (CER) on health and medical care spending interpreting CER to shift the demand for some treatments at the expense of others.

Research is about averages while clinical practice is always about the individual in the doctor's office. Balancing symptom relief with side effects is a delicate and idiosyncratic process.

Company funded trials are valuable, but more needs to be done.

President Obama's FDA commissioner should avoid actions that make the drug development process more costly and inefficient.

"Comparative effectiveness research," which, if widely adopted, could lead to much stricter government rationing of health care, is not being widely discussed.